Euro vs US Dollar

Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

Registrieren

QNCX Quince Therapeutics Inc

1,85

0,09 (5,11%)

21 Dez 2024 - Geschlossen

Verzögert um 15 Minuten

Annual Report to Security Holders (ars)

This regulatory filing also includes additional resources:
d488313dars.pdf

Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
Von Nov 2024 bis Dez 2024

Click Here for more Quince Therapeutics Charts.

Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
Von Dez 2023 bis Dez 2024

Click Here for more Quince Therapeutics Charts.

News Quince Therapeutics, Inc.

Form S-3 - Registration statement under Securities Act of 1933
Mittwoch 18 Dezember 2024 (3 Tage vor) • Edgar (US Regulatory)

Form 8-K - Current report
Donnerstag 14 November 2024 (1 Monat vor) • Edgar (US Regulatory)

Form SC 13D - General Statement of Acquisition of Beneficial Ownership
Donnerstag 14 November 2024 (1 Monat vor) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Mittwoch 13 November 2024 (1 Monat vor) • Edgar (US Regulatory)

Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
Mittwoch 13 November 2024 (1 Monat vor) • Business Wire

Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research
Dienstag 12 November 2024 (1 Monat vor) • Business Wire

Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting
Montag 11 November 2024 (1 Monat vor) • Business Wire

Quince Therapeutics to Participate at Upcoming Investor Conferences
Montag 14 Oktober 2024 (2 Monate vor) • Business Wire

Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
Dienstag 3 September 2024 (4 Monate vor) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Donnerstag 22 August 2024 (4 Monate vor) • Edgar (US Regulatory)

Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)
Donnerstag 15 August 2024 (4 Monate vor) • Business Wire

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Dienstag 13 August 2024 (4 Monate vor) • Edgar (US Regulatory)

Weitere Quince Therapeutics, Inc. News-Artikel

Premier American Uranium

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen